Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma

Table 1

Patients’ information and perioperative parameters of the sorafenib treatment group.

Patient	Gender	Age (yr)	TNM staging	Drug administration time (d)	Drug discontinuation time (d)	Drug side effects	Toxicity grading	LD before medication (cm)	LD after medication (cm)	MD before medication (HU)	MD after medication (HU)	Operation time (min)	Intraoperative blood loss (mL)	Perioperative complications	Fuhrman grading	Length of stay (d)
1	F	52	T2aN0M0	41	13	None	0	8.8	7.1	73	59	190	650	None	I	8
2	M	65	T2bN1M1	36	8	Hypertension	I	12.1	11.9	69	61	225	1980	Intraoperative hemorrhea and peritoneal damage	II	14
3	M	71	T2aN0M1	48	14	Hand-foot syndrome	I	9.1	8.2	82	77	210	530	None	II	11
4	F	69	T2aN1M1	51	16	Hypertension	I	10.5	9.6	59	56	102	810	None	II	13
5	F	73	T2aN0M0	81	7	Diarrhea	II	7.2	6.8	71	65	120	480	None	II	12

LD: longest dimension of the tumor; MD: medium density of the tumor.